DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Ottawa Marriott Hotel

2017年10月17日 (火) 午前 7:00 - 2017年10月18日 (水) 午後 3:00

100 Kent Street , Ottawa, ON K1P5R7 , CANADA

DIA Annual Canadian Meeting

Session 3B: Biosimilars: Evolving Perspectives

Session Chair(s)

Loretta  Del Bosco

Loretta Del Bosco

Director, Regulatory Affairs Quality Assurance Operations

AbbVie Corporation, Canada

Gain an overview from two key North American Regulators from Health Canada and FDA, as well as from the Alliance for Safe Biologic Medicines on the exciting and evolving landscape of Biosimilars. Being at the forefront of the biosimilar discussion is key to the future of our health care system in Canada, and abroad. This session will highlight key concepts and challenges.

Speaker(s)

Leah  Christl, PhD

FDA Update: The Development and Approval of Biosimilar Products in the US

Leah Christl, PhD

Amgen, United States

Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy

Harry  Gewanter

Understanding Canadian Prescriber Perspectives on Key Considerations for Biologics and Biosimilars

Harry Gewanter

Alliance for Safe Biologic Medicines, United States

Immediate Past Chair

Stephanie  Hardy, MPH, RAC

Biosimilars: An Update on Health Canada Activities

Stephanie Hardy, MPH, RAC

Health Canada, Canada

OPIC, Biologics and Genetic Therapies Directorate, HPFB

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。